Standardized approach of albumin, midodrine and octreotide on hepatorenal syndrome treatment response rate.

Hiruy, Aklil; Nelson, Joelle; Zori, Andreas; Morelli, Giuseppe; Cabrera, Roniel; Kamel, Amir

Hiruy, Aklil; Nelson, Joelle; Zori, Andreas; Morelli, Giuseppe; Cabrera, Roniel; Kamel, Amir.

Affiliation

Hiruy A; Department of Pharmacy, University of Florida Health Shands, Gainesville.
Nelson J; Department of Pharmacy, University Health System, San Antonio.
Zori A; Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Florida, Gainesville, Florida, USA.
Morelli G; Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Florida, Gainesville, Florida, USA.
Cabrera R; Department of Medicine, Division of Gastroenterology, Hepatology and Nutrition, University of Florida, Gainesville, Florida, USA.
Kamel A; Department of Pharmacy, University of Florida Health Shands, Gainesville.

Eur J Gastroenterol Hepatol ; 33(1): 102-106, 2021 01.

Article in En | MEDLINE | ID: mdl-32243349

Subject(s)

Hepatorenal Syndrome; Midodrine; Albumins/therapeutic use; Drug Therapy, Combination; Hepatorenal Syndrome/diagnosis; Hepatorenal Syndrome/drug therapy; Humans; Liver Cirrhosis/complications; Liver Cirrhosis/drug therapy; Midodrine/adverse effects; Octreotide/adverse effects; Retrospective Studies; Treatment Outcome; Vasoconstrictor Agents/adverse effects

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hepatorenal Syndrome / Midodrine Type of study: Diagnostic_studies / Observational_studies / Risk_factors_studies Limits: Humans Language: En Journal: Eur J Gastroenterol Hepatol Journal subject: GASTROENTEROLOGIA Year: 2021 Type: Article

Fulltext

XML

PubMed Links

Search on Google